Glaxo Wellcome/Warner-Lambert's Zantac 75 clears FDA advisory committee July 13.
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC 75 RECEIVES UNANIMOUS RECOMMENDATION FOR OTC APPROVAL at a joint meeting of the Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees on July 13. Glaxo Wellcome's Zantac 75 (ranitidine HCl) is expected to be the third H2 antagonist approved by FDA this year, following J&J/Merck's Pepcid AC and SmithKline Beecham's Tagamet HB.